Dr Reddy’s Launches Second US Vascepa Rival As Supreme Court Rejects Amarin
Appeal Refused In Litigation Involving Reddy’s And First-To-Market Hikma
Dr Reddy’s has shaken up the market for generic Vascepa in the US by launching its own icosapent ethyl capsules to compete with Hikma’s generic and the Amarin brand, hot on the heels of the Supreme Court’s rejection of the originator’s attempt to overturn a Federal Circuit decision invalidating six Vascepa patents.
